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Abstract
Background: Obstetric cholestasis (OC) is a serious problem in pregnancy. It affects about 4500
women per year in the UK. Affected women develop itching and occasionally jaundice. More
importantly, the condition is associated with premature delivery, fetal distress and is believed to be
an important cause of stillbirth. However, even now, there is no clear evidence as to whether the
most popular treatment, a drug called ursodeoxycholic acid is beneficial to the baby, or even if it is
safe in pregnancy. Nor do we know whether planned early delivery of the baby at 37–38 weeks,
another popular treatment, does more good than harm. A randomised trial to evaluate both
ursodeoxycholic acid and timed delivery is needed but will be complicated and expensive. We plan
a preliminary study, Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric
cholestasis (Acronym PITCH- Pregnancy Intervention Trial in Cholestasis) trial, to evaluate the
feasibility of a larger trial. The trial is funded by the NHS Research for Patient Benefit (RfPB)
Programme.
Methods: PITCH is a multi-centre, double blinded, randomised, controlled, factorial design trial.
The trial is being run in six UK centres and women with obstetric cholestasis will be recruited for
eighteen months. In this pilot trial we aim to collect data to finalise the design for the main trial.
This will include measuring trial recruitment rate, including recruitment to each factorial
comparison separately. We will also measure the spectrum of disease among recruits and non-
recruits and compliance with the four possible treatment allocations. We will use these data to
design the main trial.
Discussion: The ultimate aim of the main trial is to enable clinicians to manage this condition more
effectively. If it transpires that ursodeoxycholic acid and early delivery are both safe and effective
then steps will be taken to ensure that all women with OC who could benefit from them receives
this treatment. Conversely, if one or both the treatments turn out to be ineffective or even
harmful, they will be stopped and researchers will work at developing other modes of treatment.
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Background
Obstetric cholestasis (OC) is a liver condition unique to
pregnancy. It is also referred to as Intrahepatic Cholestasis
of Pregnancy (ICP). Pruritus is the characteristic symptom
[1,2] accompanied by otherwise unexplained deranged
liver enzymes [3-7] and elevated serum bile acid levels
[3,7-9]. The itching subsides almost immediately after
delivery [1,2,10] and the serum bile acid levels and the
liver enzymes normalise within 2–3 weeks of delivery
[1,10-14]. Occasionally, a patient might present with
atypical symptoms such as jaundice, steatorrhoea, nausea,
vomiting, anorexia, hepatomegaly and megalosplenia
[15]. It is typically seen in the late second and third trimes-
ter [11,16,17] although some studies have reported pres-
entation as early as six to ten weeks gestation [13,18].
Obstetric cholestasis affects between 0.7% and 1% [19]of
pregnancies in the UK. It runs a relatively benign course in
the mother. The main concern is its association with
increased rates of perinatal mortality [1,5,11-14,17,20-
24] and spontaneous preterm labour [11-13,17,20,21,23-
25]
Most UK obstetricians treat obstetric cholestasis with
ursodeoxycholic acid [26] in the belief that it reduces itch-
ing although this has not been shown in a suitably sized
randomised controlled trial (RCT). Nor has fetal benefit
or safety been adequately tested [27,28]. The latest
Cochrane review, updated in 2001 [29] included three tri-
als [30-32] involving 56 women comparing ursodeoxy-
cholic acid with placebo. No statistically significant
benefit on pruritus, or fetal outcomes was demonstrated.
Since then a further trial [28] randomised 130 women
diagnosed with obstetric cholestasis to placebo, ursodeox-
ycholic acid or dexamethasone. The only statistically sig-
nificant effects in the groups as randomised were
beneficial biochemical changes in the ursodeoxycholic
acid group. In the subgroup with the highest bile acids at
entry, ursodeoxycholic acid was associated with reduced
pruritus. Although the only fetal death occurred in the
placebo group, there was a non-significant trend towards
more meconium in the ursodeoxycholic acid group. The
latest guidelines from the RCOG (RCOG Guideline No.
43, January 2006) conclude as follows
"There are insufficient data to support the widespread use of
ursodeoxycholic acid outside of clinical trials. Women should be
aware of the lack of robust data concerning improvement in
pruritus, protection against stillbirth and safety to the fetus or
neonate."
Despite this lack of evidence about 4,500 pregnant
women are treated with ursodeoxycholic acid each year in
the UK and many more worldwide.
Delivery around 37–38 weeks is also widely practiced in
the management of obstetric cholestasis on the assump-
tion that it might pre-empt stillbirths [23]. Timed delivery
is probably the single most important treatment offered
by obstetricians. It is offered whenever the obstetrician
believes that the risks of early delivery are less than those
of awaiting labour. It is used in fetal growth restriction,
pre-eclampsia, preterm and term rupture of membranes,
diabetes, post maturity, placenta praevia and placental
abruption. It has been evaluated in randomised control-
led trials for post maturity, term and preterm rupture of
membranes, pre-eclampsia and growth restriction. 75% of
respondents in our survey indicated that they would
deliver at least some patients with obstetric cholestasis
early in the absence of fetal compromise. However, there
have been no trials of such intervention and this practice
has never been evaluated. There must be the potential for
considerable risk of harm, including the fetal death or
brain damage from iatrogenic prematurity, or of labour
that is more prolonged than it otherwise would have
been, and the maternal risks of increased operative deliv-
ery.
The RCOG guidelines (RCOG Guideline No. 43, January
2006) conclude as follows: "Obstetricians should be aware
that there are insufficient data to support or refute the popular
practice of 'early' (37 weeks of gestation) induction of labour
aimed at reducing late stillbirth."
This is why both interventions need to be evaluated in an
adequately powered randomised controlled trial. We are
in the process of designing such a trial. Although we have
had many indications of willingness to participate in such
a trial, we are unable to finalise the sample size calcula-
tions without reliable data of the spectrum of disease
severity which clinicians are prepared to recruit. To final-
ise the costings we also need a realistic recruitment rate
per centre. We therefore plan "Pilot study for trial of urso-
deoxycholic acid and/or early delivery for obstetric
cholestasis"
Methods and Study Design
In this pilot trial we aim to collect data to finalise the
design of a factorial trial for the main trial. Ethical
approval to conduct this trial was given by the Berkshire
Research Ethics Committee (Reference number 08/
H0505/7).
Primary objective
￿ Measure recruitment to the two factorial interven-
tions separately
Secondary objectives
￿ Relate recruitment rates to disease severityBMC Pregnancy and Childbirth 2009, 9:19 http://www.biomedcentral.com/1471-2393/9/19
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￿ Estimate a realistic recruitment rate for the definitive
trial
￿ Measure acceptability of randomisation among
potential participants offered trial entry
￿ Measure compliance with each treatment arm
￿ Measure the completeness of outcome data
￿ Finalise the design including the sample size calcula-
tion for the definitive trial
￿ Measure medium term (six weeks) maternal and
fetal outcomes for the definitive trial.
PITCH is a multi-centre, double-blinded, randomised,
controlled, factorial design trial. We will recruit in the
three collaborating centres and three other UK centres for
eighteen months. Centres will be asked to recruit partici-
pants with mild, moderate and severe obstetric cholestasis
defined as follows:
Mild: random bile acids ≤ 14 μmol/L, ALT > 100 U/L
Moderate: random bile acids 15–40 μmol/L
Severe: random bile acids > 40 μmol/L
There are two comparisons:
Comparison A – Ursodeoxycholic acid versus placebo
Investigational Medicinal Product (IMP) will be started at
500 mg bd. The dose will be increased in increments of
500 mg per day every 3–14 days if there is no biochemical
or clinical improvement until a maximum of 2 grams per
day is reached. Criteria for increasing the dose will be no
improvement in itching or a rise in serum Alanine
Transaminase (ALT) or bile acids. If there is no response
to this dose, the dose can be increased up to 3 grams per
day at the discretion of the treating clinician. The decision
to increase the dose will always be at the discretion of the
treating clinician.
Control group
Placebo capsule will be increased according to the same
regime. In both control and intervention groups, partici-
pants will be blind to their group allocation.
Ursodeoxycholic capsules 250 mg and matching placebo
are manufactured and supplied by Dr Falk Pharma
GmbH. Packaging and labelling to provide blinded treat-
ment packs is carried out in the production unit of the
pharmacy department,, Queen's Medical Centre (QMC),
Nottingham University Hospitals NHS Trust, UK. Sup-
plies will be packed in an approved container and labelled
with a single panel label. Subject name, randomisation
number and date of dispensing will be added to the label
as part of the dispensing process. The co-ordinating phar-
macy will add a further label to each container to identify
principal investigator, site address and contact telephone
number.
Comparison B – Early versus late delivery
Early planned delivery at between 37+0 and 37+6 weeks
gestation by final agreed estimated date of delivery (EDD)
or await spontaneous labour. For this part of the study,
only participants <38+0 weeks will be eligible. In early
delivery/await spontaneous labour group, participants
will be aware of group allocation.
We recognise that there is now evidence to support the
induction of even uncomplicated pregnancy by 40+10
weeks. Obstetricians are permitted to induce participants
in the "await spontaneous labour" group from 40+0 weeks,
or as clinical needs dictate.
Recruitment
Six UK centres will participate in the trial. Any pregnant
women with itching and either a random serum bile acid
level over 14 μmol/L, or an ALT over 100 U/L, between
24+0 and 40+6 weeks who has been diagnosed with obstet-
ric cholestasis will be approached by a member of the clin-
ical team and invited to participate in the trial. After
seeking verbal consent, the potential participant will be
referred to the local investigator. This local investigator
may be a consultant, obstetrician in training or midwife
according to local preferences. This person will give
detailed information (verbal and the appropriate partici-
pant information sheet) regarding the purpose of the trial
and procedures involved. If needed, the usual hospital
interpreter and translator services will be available to
assist with discussion of the trial, the participant informa-
tion sheets, and consent forms but the consent forms and
participant information sheets will not be available
printed in other languages. Potential participants will be
given adequate time to consider participation. Partici-
pants recruited at or after 38+0 will only be eligible for
ursodeoxycholic acid/placebo comparison. It will be
explained to the potential participant that that entry into
the trial is entirely voluntary and that their treatment and
care will not be affected by their decision.
We will record all use of ursodeoxycholic acid, other drugs
and labour induction for obstetric cholestasis outside the
trial in participating centres.
Inclusion criteria
￿ Itching in pregnancyBMC Pregnancy and Childbirth 2009, 9:19 http://www.biomedcentral.com/1471-2393/9/19
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￿ 24+0 to 37+6 weeks pregnant eligible for both com-
parisons (38+0 to 40+6 weeks eligible for ursodeoxy-
cholic acid/placebo comparison only)
￿ Bile acids > 14 μmol/L and/or ALT > 100 U/L
￿ Age 18 – 55 years
￿ Clinician responsible for care uncertain whether
ursodeoxycholic acid or early delivery is beneficial
￿ Patients who otherwise fulfil the recruitment criteria,
but incidentally have either hepatitis C, or cholelithia-
sis, or both, are eligible and may be included
￿ Women with multiple pregnancies who are other-
wise eligible may be included in the ursodeoxycholic
acid/placebo comparison only
￿ Willing to participate in the trial and able to give
informed consent
Exclusion criteria
￿ Dermatological and allergic pruritus with normal
liver enzymes
￿ Other causes of pruritus and deranged liver enzymes
(except hepatitis C and cholelithiasis)
￿ Hepatitis A, hepatitis B, pre-eclampsia, primary
hepatic disorders, alpha-1 antitrypsin deficiency and
current medications causing deranged liver enzymes
￿ Women unable or unwilling to consent
￿ Known lethal fetal anomalies
￿ Allergy to any component of the ursodeoxycholic
acid or placebo capsules
Consent
All participants will provide written informed consent.
The consent form will be signed and dated by the partici-
pant before they enter the trial. The investigator will
explain the details of the trial and provide the appropriate
participant information sheet, ensuring that the partici-
pant has sufficient time to consider participation. The
investigator will answer any questions that the participant
has concerning study participation. One copy of the con-
sent form will be kept by the participant, one will be kept
by the investigator, and a third will be retained in the par-
ticipant's hospital records. Should there be any subse-
quent amendment to the final protocol, which might
affect a participant's participation in the trial, continuing
consent will be obtained using an amended consent form
which will be signed by the participant. The process for
obtaining participant informed consent will be in accord-
ance with the Research Ethics Committee (REC) guidance,
and Good Clinical Practice (GCP) and any other regula-
tory requirements that might be introduced.
Randomised procedure
After taking an informed consent, pre-randomisation
baseline data will be collected (see additional file 1). The
recruiting investigator (researcher, clinician or midwife)
will ensure that a blood sample has been taken for a bile
acid and ALT level. If convenient a fasting sample will be
taken for bile acid. Participants will also be asked to con-
sent for placenta and/or cord blood sample to be collected
at delivery for DNA and molecular studies.
Randomisation will be via the Nottingham Clinical Trials
Unit (NCTU) using a web-based database and randomisa-
tion system. In each centre, the recruiting investigator will
have a username and password. S(he) will log on to the
trial website that hosts the trial database, confirm that the
participant eligibility criteria are all met and enter an
agreed minimum amount of registration data about the
participant and centre before randomisation is possible.
The computer will then issue a participant study identifi-
cation number which will be the unique identifier for the
trial participant. Randomisation will be stratified by the
trial centre only.
Participants will be randomised and allocated to ursode-
oxycholic acid/placebo and/or early planned delivery/
await spontaneous delivery (if < 38+0 weeks). The details
of the comparisons offered at each gestational age will dif-
fer as follows:
￿ 24+0 – 34+0 weeks:
￿ Offer ursodeoxycholic acid versus placebo imme-
diately
￿ If still undelivered at 34+1 – 37+6 weeks, offer
'early delivery' versus 'await spontaneous labour'
￿ 34+1 – 37+6 weeks
Offer full factorial trial. Participants may choose
one or the other comparison or both.
￿ Ursodeoxycholic acid versus placebo
￿ Early delivery versus await spontaneous labour
￿ ≥ 38+0 weeks
￿ Offer ursodeoxycholic acid or placebo onlyBMC Pregnancy and Childbirth 2009, 9:19 http://www.biomedcentral.com/1471-2393/9/19
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After randomisation to ursodeoxycholic acid/placebo
comparison, an online prescription form will be gener-
ated. The investigator will download and print this pre-
scription form. The participant is asked to collect the trial
IMP/placebo from the pharmacy. The local pharmacist
will select the pack with the appropriate number and issue
this to the participant. The investigator, pharmacist and
the trial participant will be blind to group allocation.
In early delivery/await spontaneous labour group, the
investigator and the trial participant will be aware of
group allocation. Obstetricians are permitted to induce
participants in the 'await spontaneous labour' group from
40+0 weeks, or as clinical needs dictate.
Weekly follow-up
After randomisation, participants will be seen weekly by
the researcher, a research midwife or their clinician as
appropriate to local conditions in the antenatal clinic or
day assessment unit. The participant will be asked to com-
plete the compliance progress data form (see additional
file 2) and the visual analogue itching scale. Blood sam-
ples will be collected weekly for ALT and bile acids and
research blood samples will be collected for women who
have consented. The frequency of fetal monitoring will
depend on the local preferences. Each centre will define its
monitoring regime.
The following data will be collected at weekly visit:
￿ Compliance progress data form
￿ Visual analogue itching scale
￿ Blood sample for serum bile acid and ALT level
￿ Use of other medications being taken by the partici-
pant
￿ Any adverse events
Follow-up at or immediately after delivery
If the participant has consented to the optional genetic
study, research samples (cord blood and placental sam-
ple) will be collected by the researcher, clinician or mid-
wife as locally appropriate at the time of delivery. After
delivery 'Outcome at hospital discharge' form (see addi-
tional file 3) will be completed by the local investigator.
Follow-up at six weeks post delivery
Study participants will be seen at six weeks post delivery
in the antenatal clinic or day assessment unit by the inves-
tigator. The 'Outcome at six weeks post delivery' form (see
additional file 4) will be completed during this visit. The
visual analogue itching scale will be scored and a blood
sample will be collected for serum bile acid and ALT level.
Research samples will be collected if consented (figure 1).
Withdrawal from the trial
Participants may withdraw from the trial either at their
own request or at the discretion of the treating clinician.
They will be made aware that this will not affect their
future care. Participants will be made aware via the partic-
ipant information sheet that should they withdraw, the
data collected to date cannot be erased and may still be
used in the final analysis. Participants who withdraw from
treatment (either ursodeoxycholic acid or placebo; early
delivery or await spontaneous labour) will remain in the
studies for follow-up and analysis. Even those who
decline to complete special follow-up arrangements will
be asked to allow pregnancy outcome data to be included
in the analysis and consent will be taken for the same.
Those participants who wish to withdraw and are not yet
randomised can be replaced but participants who with-
draw after randomisation will not be replaced.
Maintenance of randomisation codes and procedures for 
breaking code
The placebos used will be similar in appearance to the
IMP capsules. They will be provided in bottles. There will
be no marking on the capsule to suggest whether it is a
placebo or IMP. If the participants clinical condition dete-
riorates (worsening of itching, increasing bile acids and/or
ALT), the patients clinician can make the decision for
delivery as clinical needs dictate. The treatment code will
not be broken in such cases. In cases of serious adverse
event (SAE), the event shall be reported immediately of
knowledge of its occurrence to the chief investigator.
Endpoints
Primary endpoint
￿ Total recruitment rate per 1000 deliveries/annum
￿ Total recruitment rate per eligible women
Secondary endpoint
￿ Recruitment for the three subgroups of mild, moder-
ate and severe disease separately
Safety endpoints
It is not possible to define a predetermined safety end-
point for this trial. Both treatments are in common use.
All adverse events will be reported to the Data Monitoring
and Ethics Committee (DMEC).
Statistics
We have estimated that a provisional sample size for the
main factorial trial will be 1498 women (749 per group).
This would give 80% power, alpha 0.05, to show a reduc-
tion in the primary composite endpoint (fetal death orBMC Pregnancy and Childbirth 2009, 9:19 http://www.biomedcentral.com/1471-2393/9/19
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severe morbidity) from 6% to 3%. However, detailed
power calculations are not possible without measuring
the clinical spectrum of likely recruits to such a trial.
In the pilot phase we will develop and pilot the definitive
trial as follows:
At the launch meeting, collaborators will register their cur-
rent obstetric cholestasis treatment policies. All collabora-
tors will also agree to register all cases of obstetric
cholestasis in their centre. Collaborators will then return
to their centres and recruit to the trial for eighteen
months. During this time each centre will receive three
site visits from the research fellow, as well as regular news-
letters, email and phone contacts. At the end of the pilot
recruitment period each centre will produce the following
data:
￿ Total number of deliveries
￿ Number of participants identified with obstetric
cholestasis in each severity band
￿ Number recruited to the full factorial trial, and to the
ursodeoxycholic acid/placebo or the early delivery/
await spontaneous labour comparison only
￿ Number treated for obstetric cholestasis outside the
trial
￿ Compliance with treatment and outcome data as for
the definitive trial.
In the pilot phase we will recruit in each centre for eight-
een months. We recognise that strictly the most efficient
way to measure the recruitment rate in each centre would
be to recruit until a fixed number of participants, say ten,
had been enrolled. However, given the sunk costs of set-
ting up each centre, there are little extra costs from contin-
uing each centre beyond such a number. The target
sample size of the pilot of approximately ninety partici-
pants (equivalent to fifteen particpants per centre over
eighteen months, ten per centre per annum) has been
chosen to allow a reasonably precise estimate of the vari-
ous parameters for the main trial.
Flow of trial participants from recruitment to six weeks follow-up after delivery Figure 1
Flow of trial participants from recruitment to six weeks follow-up after delivery.
PITCH - Pregnancy Intervention Trial in Cholestasis
Potential study participant identified by clinician and referred to 
researchers  
34
+1 – 37
+6 38
+0 24
+0 – 34
+0
Consent to  
UDCA versus placebo 
Consent to both trials  Only offered UDCA versus placebo 
Consent 
Baseline bile acid and liver enzymes 
       Research sample* if consented
Baseline bile acid and liver enzymes 
Research sample* if consented 
Baseline bile acid and liver enzymes 
Research sample* if consented 
Randomise to UDCA versus placebo  Randomise both trials  Randomise UDCA versus placebo 
Weekly follow-up + compliance questionnaire + clinical and 
research samples* 
 Weekly follow-up + compliance questionnaire + clinical and 
research samples* 
Weekly follow-up + compliance questionnaire + clinical and 
research samples* 
If undelivered at 34
+1 to 37
+6, consent to  
delivery versus delay 
Staff/researchers complete outcome form (Appendix C) following 
delivery + research samples**
Staff/researchers complete outcome form (Appendix C) following 
delivery + research samples* * 
Randomise to delivery by 37 weeks versus await spontaneous
term delivery
Follow-up 6 weeks post delivery, complete outcome form 
(Appendix D) + clinical and research bloods* 
Follow-up 6 weeks post delivery, complete outcome form 
(Appendix D) + clinical and research bloods* 
Staff/researchers complete outcome form (Appendix C) following 
delivery + research samples** 
Follow-up 6 weeks post delivery, complete outcome form 
(Appendix D) + clinical and research bloods* 
Research sample*:   Blood sample for DNA extraction (optional, if participant consents)                                                                                                                     
Research sample**: Placental sample and cord blood sample (optional, if participant consents) BMC Pregnancy and Childbirth 2009, 9:19 http://www.biomedcentral.com/1471-2393/9/19
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1. Mean recruitment rate per centre over eighteen
months. By weighting recruitment by the size of each
unit we will model predicted recuitment for the pro-
posed centres in the main trial.
2. The proportion of moderate/severe cases. If this is
much below 50% the main trial will probably not be
feasible. Example 45/90 50% severe cases would have
95% CI of 39–61%.
3. The proportion recruiting to both comparison
groups. Example 80/90 89% 95% CI 81–94%
We cannot at this stage specify exactly what levels for each
parameter would make the main trial feasible since to some
extent they can be traded off against each other. For exam-
ple a relatively low level of severe cases recruited can be
traded off against a higher than expected overall recruit-
ment rate. The following broad parameters are suggested.
Example 1
Recruitment rate per centre of 10 per annum, of which 2/3
moderate or severe cases, >80% enter both comparison
arms, >95% compliance with ursodeoxycholic acid/placebo
comparison and >70% compliance with early delivery/await
spontaneous labour comparison. We would plan to recruit
for the main trial in 50 centres over three years. We believe
that this would probably be feasible within the UK
Example 2
Recruitment rate per centre of 5 per annum. Same propor-
tion of severe cases and same compliance levels would
require a trial with 100 centres over three years. This
would probably be too much for UK only centres. We
would consider collaboration with another one or two
European Union countries on a similar trial design.
Example 3
Recruitment rate per centre of less than 5 per annum.
Only 1/3 moderate or severe. The main trial would not be
realistically feasible. Similarly if recruitment to either the
ursodeoxycholic/placebo comparison or to the earlydeliv-
ery/await spontaneous labour comparison was below
50% we would probably drop the relevant comparison
from the main trial.
We have intentionally not drawn hard and fast rules for
going ahead or not with the main trial. At the end of the pilot
we will call a collaborators meeting of representatives of
about 50 UK centres at the RCOG at which the pilot data will
be presented, a range of trial designs will be presented, feasi-
bility will be discussed and a final decision will be taken.
Adverse events
An adverse event (AE) is any unfavourable and unin-
tended sign, symptom, syndrome or illness that develops
or worsens during the period of observation in the study.
The following will be considered adverse events:
￿ Fetal death
￿ Maternal death
An adverse event will not include:
￿ Itching
￿ Admission to hospital for delivery or fetal monitoring or
operative delivery
￿ Congenital anomaly in the offspring of a participant in
the current pregnancy
￿ Admission to special care baby unit (SCBU)
￿ A disability or incapacity
A Serious Adverse Event (SAE) is any adverse event occur-
ring following study mandated procedures, having
received ursodeoxycholic acid or placebo or waited for
spontaneous term delivery that results in any of the fol-
lowing outcomes:
￿ Death
￿ A life-threatening adverse event
￿ Inpatient hospitalisation or prolongation of existing
hospitalisation: Admission for delivery or fetal monitor-
ing, induction of labour or operative deliveries in which
no fetal or maternal complication occurs will not be
regarded as SAE.
￿ A disability/incapacity
￿ A congenital anomaly in the offspring of a participant in
the present pregnancy
Important medical events that may not result in death, be
life-threatening, or require hospitalisation may be consid-
ered a SAE when, based upon appropriate medical judg-
ment, they may jeopardise the study participant and may
require medical or surgical intervention to prevent one of
the outcomes listed in this definition. All adverse events
will be assessed for seriousness, expectedness and causal-
ity.
Seriousness
A distinction is drawn between serious and severe adverse
events. Severity is a measure of intensity whereas serious-
ness is defined using the criteria above. Hence, a severe
adverse event need not necessarily be serious.BMC Pregnancy and Childbirth 2009, 9:19 http://www.biomedcentral.com/1471-2393/9/19
Page 8 of 12
(page number not for citation purposes)
Causality
Unrelated or improbable: a clinical event including labora-
tory test abnormality with temporal relationship to trial
treatment administration which makes a causal relation-
ship incompatible or for which other drugs, chemicals or
disease provide a plausible explanation. This will be
counted as 'unrelated' for notification purposes.
Possible: a clinical event, including laboratory test abnor-
mality, with temporal relationship to trial treatment
administration which makes a causal relationship a rea-
sonable possibility, but which could also be explained by
other drugs, chemicals or concurrent disease. This will be
counted as 'related' for notification purposes.
Probable: a clinical event, including laboratory test abnor-
mality, with temporal relationship to trial treatment
administration which makes a causal relationship a rea-
sonable possibility, and is unlikely to be due to other
drugs, chemical or concurrent disease. This will be
counted as 'related' for notification purposes.
Definite: a clinical event, including laboratory test abnor-
mality, with temporal relationship to trial treatment
administration which makes a causal relationship a rea-
sonable possibility, and which can definitely not be attrib-
uted to other causes. This will be counted as 'related' for
notification purposes.
An adverse event whose causal relationship to the study IMP
is assessed by the chief investigator as 'possible', 'probable',
or 'definite' is an Adverse Drug Reaction (ADR). Medical and
scientific judgment shall be used in deciding whether
prompt reporting is appropriate in that situation.
Reporting of adverse events
Participants will be asked to contact the study site imme-
diately in the event of any serious adverse event. All
adverse events will be recorded and closely monitored
until resolution, stabilisation, or until it has been shown
that the study medication or treatment is not the cause.
The Chief Investigator shall be informed immediately of
any serious adverse events and shall determine serious-
ness and causality in conjunction with any treating medi-
cal practitioners. NCTU standard operating procedure
(SOP) for adverse event reporting will be followed.
All serious adverse events will be recorded and reported to
the Medicines and Healthcare products Regulatory Agency
(MHRA) and Research Ethics Committee (REC) as part of
the annual reports. Suspected Unexpected Serious Adverse
Reactions (SUSARs) will be reported within the statutory
timeframes to the MHRA and REC, as stated below. The
Chief Investigator shall be responsible for all adverse
event reporting.
Suspected Unexpected Serious Adverse Reactions (SUSARs)
A serious adverse event that is sudden in its onset, unex-
pected in its severity and seriousness or not a known side
effect of the IMP and related or suspected to be related to
the IMP is classed as SUSAR and requires expedited report-
ing as per the clinical trials regulations. All serious adverse
events that fall or are suspected to fall within these criteria
shall be treated as a SUSAR until deemed otherwise. The
event shall be reported immediately of knowledge of its
occurrence to the Chief Investigator.
The Chief Investigator will:
￿ Assess the event for seriousness, expectedness and
relatedness to the study IMP
￿ Take appropriate medical action, which may include
halting the trial and inform the sponsor of such action
￿ If the event is deemed a SUSAR, shall, within seven
days, complete the Council for International Organi-
zations and Medical Sciences (CIOMS) form and send
to the MHRA
￿ Shall inform the REC using the reporting form found
on the National Research Ethics Service (NRES) web
page within seven days of knowledge of the event
￿ Shall, within a further eight days send any follow-up
information and reports to the MHRA and REC.
￿ Make any amendments as required to the study pro-
tocol and inform the ethics and regulatory authorities
as required
Participant removal from the study due to adverse events
Any participant who experiences an adverse event may be
withdrawn from the study at the discretion of the Chief
Investigator.
Ethics committee and regulatory approvals
The trial will not be initiated before the protocol,
informed consent forms and participant information
sheets and GP letter have received approval/favourable
opinion from the MHRA, REC, and the respective
National Health Service (NHS) Research & Development
(R&D) department. Should a protocol amendment be
made that requires REC approval, the changes in the pro-
tocol will not be instituted until the amendment and
revised informed consent forms and participant informa-
tion sheets and GP letter have been reviewed and received
approval/favourable opinion from the REC and R&D
departments. A protocol amendment intended to elimi-
nate an apparent immediate hazard to participants may
be implemented immediately providing that the MHRA,BMC Pregnancy and Childbirth 2009, 9:19 http://www.biomedcentral.com/1471-2393/9/19
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R&D and REC are notified as soon as possible and an
approval is requested. Minor protocol amendments only
for logistical or administrative changes may be imple-
mented immediately; and the REC will be informed.
The trial will be conducted in accordance with the ethical
principles that have their origin in the Declaration of Hel-
sinki, 1996; the principles of Good Clinical Practice
(GCP) and in accordance with the Medicines for Human
Use Regulations, Statutory Instrument 2004, 1031 and its
subsequent amendments.
Records
Drug accountability
Drug supplies will be kept in a secure, limited access stor-
age area under the storage conditions specified by the
pharmacy. The investigator and the local site pharmacist
shall maintain records of the study drug's delivery to the
pharmacy, an inventory at the site, the distribution to
each participant, and the return to the pharmacy or alter-
native disposition of unused study drugs. These records
will include dates, quantities received, batch/serial num-
bers, expiration dates, and the participant study identifica-
tion number assigned to the trial participant. Investigators
and/or the local site pharmacists will maintain records
that document adequately that the participants were pro-
vided with the correct study medication. These records
will be part of each participant's Case Report Form (CRF).
All study medication packs and bottles received by the
pharmacy shall be accounted for.
Case Report Forms
Each participant will be assigned a participant study iden-
tity code number, allocated at randomisation, for use on
CRFs, other trial documents and the electronic database.
The documents and database will also use their initials (of
first and last names separated by a hyphen or a middle
name initial when available) and date of birth (dd/mm/
yy). CRFs will be treated as confidential documents and
held securely in accordance with regulations. The investi-
gator will make a separate confidential record of the par-
ticipant's name, date of birth, local hospital number or
NHS number, and participant study identification
number to permit identification of all participants
enrolled in the trial, in case additional follow-up is
required. CRFs shall be restricted to those personnel
approved by the Chief or local Principal Investigator and
recorded on the Trial Delegation Log (TDL). All paper
forms shall be filled in using black ballpoint pen. Errors
shall be lined out but not obliterated by using correction
fluid and the correction inserted, initialled and dated. The
Chief or local Principal Investigator shall sign a declara-
tion ensuring accuracy of data recorded in the CRF.
Source documents
Source documents shall be filed at the investigator's site
and may include but are not limited to, consent forms,
current medical records, laboratory results and pharmacy
records. A CRF may also completely serve as its own
source data. Only trial staff as listed on the TDL shall have
access to trial documentation other that the regulatory
requirements listed below.
Direct access to source data/document
The CRF and all source documents, including progress
notes and copies of laboratory and medical test results
shall made be available at all times for review by the Chief
Investigator, Sponsor's designee and inspection by rele-
vant regulatory authorities.
Data protection
All trial staff and investigators will endeavour to protect
the rights of the trial participants to privacy and informed
consent, and will adhere to the Data Protection Act, 1998.
The CRF will only collect the minimum required informa-
tion for the purposes of the trial. CRFs will be held
securely, in a locked room, or locked cupboard or cabinet.
Access to the information will be limited to the trial staff
and investigators and relevant regulatory authorities.
Computer held data including the trial database will be
held securely and password protected. All data will be
stored on a secure dedicated web server. Access will be
restricted by user identifiers and passwords (encrypted
using a one way encryption method). Information about
the trial in the participant's medical records/hospital
notes will be treated confidentially in the same way as all
other confidential medical information. Electronic data
will be backed up every 24 hours to both local and remote
media in encrypted format.
Trial management
The management of the PITCH trial includes an element of
advice that is completely independent from the principal
investigators and their host institutions. We shall appoint a
Trial Steering Committee (TSC) including an independent
chair, an independent expert member and a lay member.
The TSC will provide overall supervision of the trial, in par-
ticular, trial progress, adherence to the protocol, patient
safety and the consideration of new information.
A Data Monitoring and Ethics Committee (DMEC) will be
established. Members of DMEC will meet regularly to
view data and the results of any interim analyses. During
the pilot phase we propose that there be no formal stop-
ping rules. However, the DMEC will review unblinded
data at least annually together with all reported adverse
drug reactions as they accrue. We will recruit to the pilotBMC Pregnancy and Childbirth 2009, 9:19 http://www.biomedcentral.com/1471-2393/9/19
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study for eighteen months. It will cease earlier if the
DMEC recommends stopping. DMEC members will be
independent of both the trial and TSC.
Insurance and indemnity
Insurance and indemnity for trial participants and trial
staff is covered within the NHS Indemnity Arrangements
for clinical negligence claims in the NHS, issued under
cover of HSG (96)48. There are no special compensation
arrangements, but trial participants may have recourse
through the NHS complaints procedures.
Trial conduct
Trial conduct will be subject to systems audit of the Trial
Master File (TMF) for inclusion of essential documents;
permissions to conduct the trial; TDL; curriculum vitae of
trial staff and training received; local document control
procedures; consent procedures and recruitment logs;
adherence to procedures defined in the protocol (e.g.
inclusion/exclusion criteria, correct randomisation, time-
liness of visits); adverse event recording and reporting;
drug accountability and pharmacy records. The Trial Man-
ager, or where required, a nominated designee of the
Sponsor, shall carry out a site systems audit at least yearly
and an audit report shall be made to the TSC.
Trial data
Monitoring of trial data shall include confirmation of
informed consent; source data verification; data storage
and data transfer procedures; local quality control checks
and procedures, back-up and disaster recovery of any local
databases and validation of data manipulation. The Trial
Manager, or where required, a nominated designee of the
Sponsor, shall carry out monitoring of trial data as an
ongoing activity.
Entries on CRFs will be verified by inspection against the
source data. A sample of CRFs (10%) will be checked on a
regular basis for verification of all entries made. In addition
the subsequent capture of the data on the trial database will
be checked. Where corrections are required these will carry
a full audit trail and justification. Trial data and evidence of
monitoring and systems audits will be made available for
inspection by the regulatory authority as required.
Record retention and archiving
In compliance with the ICH/GCP guidelines, regulations
and in accordance with the University of Nottingham
Research Code of Conduct, the Chief or local Principal
Investigator will maintain all records and documents
regarding the conduct of the study. These will be retained
for at least seven years or for longer if required. If the
responsible investigator is no longer able to maintain the
study records, a second person will be nominated to take
over this responsibility.
The TMF and trial documents held by the Chief Investiga-
tor on behalf of the Sponsor shall be finally archived at
secure archive facilities at the University of Nottingham.
This archive shall include all trial databases and associated
meta-data encryption codes.
Discontinuation of the trial by the sponsor
The Sponsor reserves the right to discontinue this trial at
any time for failure to meet expected enrolment goals, for
safety or any other administrative reasons. The sponsor
shall take advice from the TSC and DMEC as appropriate
in making this decision.
Statement of confidentiality
Individual participant medical information obtained as a
result of this study is considered confidential and disclo-
sure to third parties is prohibited with the exceptions
noted above. Participant confidentiality will be further
ensured by utilising participant study identification num-
bers to correspond to treatment data in the computer files.
Such medical information may be given to the partici-
pant's medical team and all appropriate medical person-
nel responsible for the participant's welfare. Data
generated as a result of this trial will be available for
inspection on request by the participating physicians, the
University of Nottingham representatives, the REC, local
R&D Departments and the regulatory authorities.
Funding source
The NHS Research for Patient Benefit programme (East
Midlands) and Nottingham University Hospitals NHS
Trust are funding the pilot study. Funding is being admin-
istered by the University of Nottingham.
Participant stipends and payments
Participants will not be paid to participate in the trial.
Each centre will be paid £300 per participant for the
expenses.
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